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ABSTRACT 
Research has suggested roles of vitamin D in health beyond its action on calcium 
homeostasis and bone health. Recent studies revealed a high proportion of pregnant women 
having low vitamin D status. This may lead to increased risks for preeclampsia, gestational 
diabetes (GDM), and cesarean delivery. Findings on the effects of vitamin D on these adverse 
pregnancy outcomes have been inconsistent. To our knowledge, no studies have examined 
maternal vitamin D status with circulating triacylglycerol (TAG) concentrations. 
This study was conducted to assess the effects of maternal vitamin D status on subsequent 
risk for pregnancy complications and to determine the effectiveness of 25-hydroxyvitamin D 
[25(OH)D] to TAG ratio to indicate vitamin D status. We measured the plasma 25(OH)D and 
TAG concentrations of 299 pregnant women in their 8
th
 to 20
th
 week of gestation, and examined 
the association between 25(OH)D concentrations, 25(OH)D/TAG ratios and the risk of 
preeclampsia, GDM, and cesarean delivery. 
Of the 299 subjects, five developed preeclampsia, 15 developed GDM, and 89 delivered their 
infants by cesarean section. Women diagnosed with preeclampsia or GDM had significantly 
lower 25(OH)D/TAG ratios than women without these complications. Women with 25(OH)D 
concentrations and 25(OH)D/TAG below medians had increased odds of preeclampsia (OR, 4.05; 
95% CI, 0.45-36.71 and OR, 4.05; 95% CI, 0.45-36.71 respectively) and GDM (OR, 2.12; 95% 
CI, 0.71-6.38 and OR, 2.96, 95% CI, 0.92-9.55 respectively). These results were not statistically 
significant because of the small number of affected women, but the association between 
25(OH)D/TAG and GDM risk was close to significant (P = 0.07). Women with 25(OH)D 
concentrations and 25(OH)D/TAG below medians also had reduced odds for cesarean delivery 
(OR, 0.54; 95% CI, 0.32-0.89 and OR, 0.74; 95% CI, 0.45-1.22 respectively), but only the 
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association between 25(OH)D concentration and risk of cesarean delivery was statistically 
significant.  
This study suggested increased preeclampsia and GDM risks in women with low vitamin D 
status. Few cases of these events compromised the statistical significance of results. The 
increased risk of cesarean delivery in women with higher vitamin D status shown has to be 
reevaluated because reasons for cesarean delivery were not included in the analysis.   
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Chapter 1 
INTRODUCTION 
Studies has shown vitamin D to be an important nutrient for skeletal growth and bone health 
(1). It helps to maintain calcium homeostasis by increasing intestinal absorption and renal 
reabsorption of calcium and phosphorus, regulating parathyroid secretion, and regulating bone 
calcium mobilization (2). Vitamin D deficiency results in rickets in children and osteomalacia in 
adults (1). The presence of vitamin D receptors in the pancreas, T lymphocytes and other tissues 
suggests that vitamin D may have other beneficial effects on health besides bone health, such as 
immunomodulation, cell differentiation, and muscle strengthening (2, 3). 
Several studies (4-7) examined the vitamin D status of pregnant women in the US since 2007. 
They showed poor vitamin D status of US women during early pregnancy. Studies found an 
inverse association between maternal vitamin D status during pregnancy and risk for 
preeclampsia (8-11), gestational diabetes (12-14), and cesarean section (15). There are relatively 
few studies done, and their findings are inconsistent. Additional studies are needed to support the 
relationship between maternal vitamin D status and these pregnancy outcomes. 
Maternal circulating triacylglycerol (TAG) increases dramatically with weeks of gestation 
(16). The assessment of maternal vitamin D status may not be accurate without taking the 
significant increase in circulating TAG throughout pregnancy into consideration. This may be 
the reason why the findings of vitamin D studies during pregnancy are inconsistent. Therefore, 
studies to examine the effect of circulating 25(OH)D in relation to circulating TAG on pregnancy 
outcomes are necessary. 
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Statement of Purpose 
The purpose of this study was to determine the vitamin D status of a cohort of pregnant 
women in Kansas City metropolitan area, to assess its relationship with adverse pregnancy 
outcomes, and to examine if plasma 25(OH)D concentrations relative to circulating TAG 
concentrations will be a better indicator of maternal vitamin D status. 
Research Questions 
The primary research question is: Should plasma 25(OH)D concentration be adjusted for 
circulating triacylglycerol concentration in assessing maternal vitamin D status? 
The secondary research questions are: 
1) What is the prevalence of vitamin D deficiency (25(OH)D <50 nmol/L) and the prevalence of 
vitamin D insufficiency (25(OH)D 50-75 nmol/L) in a Kansas City cohort of pregnant women? 
2) Does the maternal vitamin D status during pregnancy relate to adverse pregnancy outcomes?  
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Chapter 2 
REVIEW OF LITERATURE 
Vitamin D Metabolism 
Two major forms of vitamin D exist. Ergocalciferol (vitamin D2) is a 28-carbon derivative of 
ergosterol synthesized by yeasts and fungi, and cholecalciferol (vitamin D3) is a 27-carbon 
derivative of cholesterol synthesized in animal and human skin after exposure to ultraviolet B 
irradiation (1, 17, 18). The term “vitamin D” will be used to represent both vitamin D2 and 
vitamin D3 in the rest of this thesis, unless otherwise specified. 
After the ingestion of vitamin D, it is absorbed within the small intestine. Vitamin D is 
subsequently incorporated into the chylomicrons by the enterocytes, and enters the lymphatic 
system (19). The endogenously produced vitamin D3 in the skin enters the bloodstream and is 
bound either tightly to vitamin D binding protein (DBP) or loosely to albumin or lipoproteins (18, 
20). When vitamin D reaches the liver, it is hydroxylated by hepatic 25-hydroxylase to form 
25(OH)D, which is the major circulating and storage form of vitamin D metabolites, and the 
major indicator used to measure vitamin D status. In the kidney or certain extrarenal tissues, such 
as placenta (21), 25(OH)D can be hydroxylated by 1α-hydroxylase (1-α-OHase) to form 1,25-
dihydroxyvitamin D (1,25(OH)2D), the active form of vitamin D (19). Both 25(OH)D and 
1,25(OH)2D can be hydroxylated by renal or extrarenal 24-hydroxylase to form more polar 
metabolites for excretion (19, 22). 
Mechanism of Action 
Circulating 1,25(OH)2D regulates over numerous genes (18, 23). It acts through binding to a 
nuclear receptor, the vitamin D receptor (VDR). The VDR in turn forms a heterodimer with the 
retinoid X receptor and binds to the promoter region of the target gene. The subsequent binding 
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of co-activators or co-repressors to the heterodimer will induce or repress the transcription of the 
gene (17). VDR may also be associated with the plasma membrane, and its binding to 
1,25(OH)2D activates second messenger system(s) and results in rapid non-genomic responses 
(24). Vitamin D performs a variety of physiological functions primarily through these 
mechanisms. 
Challenges in Vitamin D Studies 
There is no consensus on the definition of vitamin D deficiency, insufficiency, and 
sufficiency in terms of circulating 25(OH)D concentration. Different combinations of cut points 
have been used to define vitamin D status by different investigators. Commonly used cut points 
include 25 nmol/L (13, 25, 26), 37.5 nmol/L (6, 9, 15, 27), 50 nmol/L (4, 5, 8, 11, 25-27), 75 
nmol/L (4, 9, 11, 12), and 80 nmol/L (5, 6, 8, 26). 
The accuracy of the measurement of 25(OH)D concentrations varies with the assay methods 
and the technicians. The interlaboratory variability in 25(OH)D measurement is so substantial 
that an individual considered to be sufficient in vitamin D in one laboratory may appear to have 
vitamin D insufficiency in another laboratory (28). Also, many assay methods underestimate 
vitamin D2 concentrations (29-31). These factors make interpreting and comparing the results of 
vitamin D studies challenging. 
Vitamin D in Pregnancy 
Maternal circulating 1,25(OH)2D concentrations increase from pre-pregnancy values starting 
from the first trimester, and can double or triple the pre-pregnancy values in the second and the 
third trimester (32). This increase in maternal 1,25(OH)2D concentrations may help the fetus to 
accrete about 30 g of calcium for development during pregnancy (33) and may be important for 
normal pregnancy. Therefore, vitamin D requirement is increased during pregnancy. 
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Studies have shown a majority of pregnant women in the US have suboptimal vitamin D 
status, even with a high rate of prenatal vitamin consumption. Ginde et al. (4) selected 928 
pregnant women and 5,173 non-pregnant women from the NHANES database between 2001 and 
2006. They determined the prevalence of vitamin D insufficiency, defined as serum 25-
hydroxyvitamin D (25(OH)D) <50 nmol/L or <75 nmol/L, among pregnant women and non-
pregnant women. This study reported 42% and 78% of non-pregnant women had serum 
25(OH)D concentrations less than 50 nmol/L and 75 nmol/L respectively, while 46% and 83% of 
pregnant women in their first trimesters had serum 25(OH)D concentrations less than 50 nmol/L 
and 75 nmol/L respectively. A study conducted in South Carolina found 41% of pregnant women 
were deficient in vitamin D (25(OH)D <50 nmol/L) and another 41% of pregnant women were 
insufficient in vitamin D (25(OH)D 50-80 nmol/L) during early pregnancy (5). Another 
Pennsylvania study found 62% of Caucasian pregnant women and 96% of African American 
pregnant women were deficient or insufficient (25(OH)D <80 nmol/L) in vitamin D during early 
pregnancy (6). A small study examined the prevalence of vitamin D deficiency and insufficiency 
in 80 pregnant African American adolescents and revealed that 52% and 36% of African 
American adolescents were low (25(OH)D <50 nmol/L) in vitamin D during the second and third 
trimester respectively (27). 
This suboptimal maternal vitamin D status may predispose their infants to adverse conditions 
including rickets because maternal and infant serum 25(OH)D concentrations are highly 
correlated (34, 35). Hollis et al. (36) reported neonatal 25(OH)D concentrations were about half 
of maternal 25(OH)D concentrations. Vitamin D status in pregnant women warrants increased 
attention. 
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Vitamin D and Preeclampsia 
Preeclampsia occurs in about 3% of pregnancies in the United States (37). It is usually 
diagnosed after 20 weeks of gestation. A characteristic of preeclampsia is hypertension—systolic 
blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg in women normotensive 
before 20 weeks of gestation—with some degree of proteinuria (38). Risk factors for 
preeclampsia include previous history of preeclampsia, preexisting diabetes and multifetal 
pregnancy (38). Preeclampsia is associated with a number of complications, such as preterm 
delivery and fetal growth restriction (39). 
The pathogenesis of preeclampsia is still unclear, but it seems to be related to abnormal 
placentation, reduced placental perfusion, and abnormal maternal inflammatory response (39). 
An imbalance of proimflammatory Th1-type cytokines and anti-inflammatory Th2-type 
cytokines was found in preeclamptic women, with a higher Th1 to Th2 ratio (40). Placentas of 
preeclamptic women were also found to have significantly lower vascular endothelial growth 
factor (VEGF) (18) and lower 1-α-OHase expression and activity, compared to the placentas 
from uncomplicated pregnancies (41). 
Studies support the idea that lower vitamin D status may play a role in the development of 
preeclampsia. The active form of the vitamin [1,25(OH)2D] was proposed to be important for 
normal placentation, angiogenesis, and immunological tolerance for normal implantation. For 
example, 1, 25(OH)2D is anti-inflammatory by down-regulating the expression of Th1-type 
cytokines and up-regulating Th2-type cytokines (42, 43). Also, it enhances the expression of 
HOXA10, an important gene for implantation (44), and up-regulates VEGF for angiogenesis (45). 
The vitamin D status of women at conception and during early pregnancy is likely a risk factor 
for preeclampsia. 
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Research studies found an inverse relationship between maternal vitamin D status during 
pregnancy and risk for preeclampsia. A nested case-control study reported significantly lower 
serum 25(OH)D concentrations at less than 22 weeks of gestation in 55 women who 
subsequently developed preeclampsia compared to 219 non-preeclamptic controls (9). Another 
nested case-control study of 43 cases and 198 controls reported women with serum 25(OH)D 
concentrations <50 nmol/L between the 15
th
 and 20
th
 week of gestation was associated with a 5-
fold increased risk of developing severe preeclampsia, when compared to women with serum 
25(OH)D concentrations >75 nmol/L (11). Robinson et al. (8) measured maternal plasma 
25(OH)D concentrations of 50 women at the time of diagnosis of early-onset severe 
preeclampsia (EOSPE)—severe preeclampsia diagnosed before 34 weeks of gestation—and 
compared these with the concentrations of the 100 control pregnant women. They reported a 
63% decreased odds of EOSPE with every 25-nmol/L increase in the plasma 25(OH)D 
concentrations of the EOSPE patients. Haugen et al. (10) measured the vitamin D intake of 
23,423 women during pregnancy. They found women who developed preeclampsia had 
significantly lower supplemental vitamin D intake during pregnancy compared to women who 
were non-preeclamptic. 
In contrast, Powe et al. (46) found no significant differences in maternal serum 25(OH)D 
concentrations during the first trimester between 39 preeclamptic subjects and 131 non-
preeclamptic subjects. They concluded that maternal 25(OH)D concentrations in the first 
trimester were not associated with the risk of subsequent preeclmpsia. 
Vitamin D and Gestational Diabetes Mellitus 
GDM is diagnosed between 24 and 28 weeks of gestation, or earlier if a woman has 
increased risk for GDM. To screen for GDM, a 1 hour 50-g oral glucose tolerance test (OGTT) is 
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usually done. This is followed by a 3 hour 100-g OGTT if the 1 hour test yields a positive result. 
Two or more abnormal values in the 3 hour test lead to the diagnosis of GDM. Risk factors of 
GDM include increasing maternal age, obesity, previous history of GDM, family history of 
diabetes mellitus, previous delivery of an infant with macrosomia, and recurrent miscarriages 
(13). GDM increases the risk of fetal macrosomia, which may lead to a cesarean delivery, and 
the woman’s risk of developing metabolic syndrome and type 2 diabetes (47).  
In pregnant women with GDM, pancreatic β cells fail to increase insulin secretion in 
response to the reduced insulin sensitivity during pregnancy (47). Both VDR and 1-α-OHase are 
expressed in pancreatic islets (1). Vitamin D is also known to improve insulin sensitivity by 
enhancing the expression of insulin receptors (48). Vitamin D may reduce the risk of GDM by 
regulating insulin release and insulin sensitivity (49). 
Soheilykhah et al. (14) compared the serum 25(OH)D concentrations in 54 pregnant women 
with GDM, 39 pregnant women with impaired glucose tolerance (IGT), and 111 pregnant 
women with normal glucose tolerance at 24-28 weeks of gestation. They reported a significantly 
lower vitamin D status in the GDM and the IGT groups (P = 0.001). A cross-sectional study 
involving 741 pregnant Iranian women showed that gestational diabetes was significantly more 
prevalent in women with 25(OH)D3 <12.5 nmol/L than women with 25(OH)D3 >34.9 nmol/L. 
The same study showed maternal serum 25(OH)D concentration is inversely associated with 
insulin resistance indicated by the HOMA index values, which is an insulin resistance index 
calculated from the fasting plasma glucose and the fasting plasma insulin concentrations (13). 
This association was confirmed in a cohort study involving 307 pregnant women (50). 
In contrast, Farrant et al. (51) found no association between maternal serum 25(OH)D 
concentration during pregnancy and risk for gestational diabetes in a study of 559 Indian women. 
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Vitamin D and Cesarean Section 
About 32% of births in the US are delivered by cesarean section (52). Low maternal vitamin 
D status during pregnancy may be a risk factor for primary cesarean delivery. Merewood et al. 
(15) measured vitamin D concentrations of 253 mothers after delivery. They reported that the 
risk for primary cesarean section in women with vitamin D concentrations <37.5 nmol/L was 
almost four times higher than women with higher vitamin D concentrations. They proposed 
maternal vitamin D status may be associated with risk for primary cesarean section through 
calcium’s role in the initiation of labor, or by increasing preeclampsia risk. Studies revealed a 
significant increase in maternal serum calcium concentrations at the time of vaginal delivery (53), 
and suggested the role of serum calcium in smooth muscle function in labor (54). In contrast, 
Bowyer et al. (25) found no significant association between maternal 25(OH)D concentrations 
and mode of delivery in a study of 971 pregnant women. 
Vitamin D and Triacylglycerol 
A longitudinal study of 2159 subjects in Norway reported a significant inverse association 
between serum 25(OH)D and TAG in adults (55). This inverse association was also found in a 
cross-sectional study of 909 subjects in Finland (β = -0.17, P < 0.001) (56). However, other 
studies did not support this association (57, 58). To the best of our knowledge, no previous 
studies have examined both circulating 25(OH)D and TAG concentrations in pregnant women. 
During pregnancy, maternal circulating TAG increases dramatically with weeks of gestation due 
to increased mobilization of maternal fat stores to provide fatty acids for the fetus (16). This 
increased mobilization of maternal fat stores could influence the amount of 25(OH)D carried in 
the plasma because vitamin D is a fat-soluble vitamin and is stored in adipose tissue (2). Higher 
circulating vitamin D concentrations may not necessarily reflect better vitamin D status when 
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circulating TAG concentrations are taken into account. Plasma 25(OH)D concentration to TAG 
concentration ratio may be a better measure of vitamin D status during pregnancy and may help 
to explain the inconsistent results of vitamin D studies on pregnancy.  
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Chapter 3 
METHODS 
Overview 
The purpose of this study was to determine the vitamin D status of a cohort of pregnant 
women in Kansas City metropolitan area, to assess its relationship with adverse pregnancy 
outcomes, and to examine if plasma 25(OH)D concentrations relative to circulating TAG 
concentrations would be a better indicator of vitamin D status. 
Sample 
This study used a sample of subjects from the Kansas University DHA Outcomes Study 
(KUDOS), a double-blind, randomized clinical trial designed to determine whether increased 
prenatal docosahexaenoic acid (DHA) intake would improve pregnancy outcomes and the 
cognitive development of infants. The subjects were randomly assigned to one of two groups—
one consumed capsules with DHA-oil and the other consumed capsules with ordinary food oil. 
Pregnant women aged 16-35 years, in their 8
th
 to 20
th
 week of gestation, with BMI <40, who 
agreed to return to the study center for delivery were included in the trial. Pregnant women who 
had multiple fetuses in the index pregnancy, serious illness, diabetes or gestational diabetes, 
elevated blood pressure at baseline, and were unable or unwilling to consume the study capsules 
until delivery were excluded. 350 pregnant women who met these criteria were enrolled in the 
KUDOS trial. This vitamin D study was based on the data of the 299 women who had 
information at delivery. 
Setting 
The subjects were recruited from April 2006 to November 2009 at University of Kansas 
Medical Center (KUMC) in Kansas City, Kansas, Truman Medical Center in Kansas City, 
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Missouri, and St. Luke’s Hospital in Kansas City, Missouri where the women planned to deliver 
their infants. Women who responded to a broadcast e-mail at KUMC were also enrolled and they 
delivered at the hospitals mentioned and five additional area hospitals. 
Ethics 
The procedures and protocols of the KUDOS trial were approved by Human Subjects 
Committee at University of Kansas Medical Center (HSC#10186), and this vitamin D study is 
covered under the KUDOS protocol because it involves nutritional assessment from available 
blood samples. 
Procedure 
Informed consent was obtained from each subject. Non-fasting blood samples were drawn 
from the women at enrollment and were stored at -80°C after separating into plasma and red 
blood cell samples. Weight and blood pressure were measured, and other maternal characteristics 
(years of education, prenatal vitamin use, smoking status, etc.) were self-reported at enrollment. 
Maternal body mass index (BMI) was calculated from measured weight at enrollment and either 
measured or reported height. Race was self-reported as African American, Caucasian, Hispanic, 
or Other. Subjects within the “Other” category included Indian American, Hawaiian, and Korean. 
Due to the small number of subjects in that category (n = 3), they were combined with the 
Hispanic group for statistical analyses. Medical records were reviewed for information on 
preeclampsia, GDM, and the mode of delivery for the index pregnancy. 
Plasma samples collected at enrollment were used for 25(OH)D and TAG assays. One of the 
299 subjects lacked plasma sample at enrollment, and the postpartum plasma sample of this 
subject collected within two days of delivery was used instead. 
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Vitamin D deficiency, insufficiency and sufficiency were defined as plasma 25(OH)D below 
50 nmol/L, 50-75 nmol/L and above 75 nmol/L respectively in this study. These cutoffs were 
chosen because they have been used in recently published studies (5, 8, 11, 12, 14). We expect 
that our results would be more comparable to the findings of recent studies by using these cutoffs. 
Also, 25(OH)D less than 50 nmol/L may be associated with increased risk of nonskeletal chronic 
diseases (59) and 25(OH)D concentrations above 75 nmol/L may be required to prevent 
secondary hyperparathyroidism (60). 
For the purpose of this study, adverse pregnancy outcomes include the diagnosis of 
preeclampsia or GDM, or having a cesarean delivery in the index pregnancy. A subject was 
considered to have adverse pregnancy outcomes when at least one of these conditions occurred. 
In this study, 18 subjects did not have complete oral challenge test results, and no diagnosis of 
GDM could be made. They were thus excluded in the statistical analyses of GDM and adverse 
pregnancy outcomes. 
Laboratory Assays 
Plasma 25(OH)D concentration was analyzed by the Kansas Intellectual and Developmental 
Disabilities Research Center (K-IDDRC) laboratory using an enzyme-linked immunosorbent 
assay (ELISA) kit (Immundiagnostik AG, Bensheim, Germany). The assay could detect 
25(OH)D concentrations as low as 3.2 nmol/L. The intra- and inter-assay coefficients of 
variation for the ELISA were both 7.0%. The ELISA recognizes 100% of 25(OH)D3 and 67.8% 
of 25(OH)D2. The 25(OH)D concentrations obtained from the ELISA and HPLC were highly 
correlated (r = 0.943) (61). The 25(OH)D assay procedure is described in Appendix A. 
Plasma TAG analysis was performed using a triglyceride assay kit from Cayman Chemical 
Company, Michigan, USA. The assay could detect TAG in the range of 0-200 mg/dL. One 
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sample had a TAG concentration higher than 200 mg/dL, and its concentration was calculated 
from the absorbance value using the standard curve equation. The intra-assay and the inter-assay 
coefficients of variations for the triglyceride assay kit were 1.34% and 3.17% respectively (62). 
The TAG assay procedure is described in Appendix B. 
Statistical Analysis 
Continuous variables are presented as mean ± standard deviation, and categorical variables as 
the number of observations (percentage). The characteristics of the subjects were reported by 
race. The characteristics of the subjects with adverse pregnancy outcomes were evaluated by 
comparing them to subjects without experience any adverse pregnancy outcomes during the 
index pregnancy. The risks for preeclampsia, GDM, and cesarean section among pregnant 
women with plasma 25(OH)D concentrations and the 25(OH)D/TAG ratio below the medians 
were compared to those above the medians, and were presented as odds ratios and 95% 
confidence intervals (95% CI). Mean ± standard deviation of plasma 25(OH)D, TAG, and 
25(OH)D/TAG ratio within each category of various maternal factors was reported to assess 
their effects on maternal vitamin D status. 
The differences in maternal characteristics between groups were assessed by independent 
sample t-tests for continuous variables and by chi-square tests for categorical variables. Fisher’s 
exact test was used in place of chi-square test when more than 20% of the cells have an expected 
frequency below five. Plasma 25(OH)D concentrations, TAG concentrations, 25(OH)D/TAG 
ratios, and maternal years of education were log-transformed before t-tests were performed, 
because the distributions of these variables were skewed.  
Results were considered statistical significant if two-tailed P values <0.05. Statistical 
analyses were performed using PASW Statistics 18. 
15 
 
Chapter 4 
RESULTS 
This study was conducted to determine the vitamin D status of the cohort of pregnant women, 
to assess its relationship with adverse pregnancy outcomes, and to examine if plasma 
25(OH)D/TAG ratio would be a better indicator of vitamin D status. 
Subject Characteristics 
In this study, African American women and Hispanic women were younger, had a higher 
BMI, were less educated, were more likely to be multiparous, and tended to start taking prenatal 
vitamins later in gestation than Caucasian women (Table 1). Hispanic women tended to have a 
lower systolic blood pressure at enrollment compared with African American women (108 ± 
10.6 mm Hg vs. 114 ± 10.2 mm Hg; P = 0.02) and Caucasian women (108 ± 10.6 mm Hg vs. 
115 ± 9.4 mm Hg; P = 0.001). No significant differences between race groups in the gestational 
age when blood was drawn (data not shown) and the season of blood collection were observed. 
Maternal 25(OH)D concentrations of the Caucasian women were the highest among the three 
race groups, and were almost two times the 25(OH)D concentrations of African American 
women (64.2 ± 32.2 nmol/L vs. 33.9 ± 20.8 nmol/L; P < 0.001). Hispanic women had maternal 
25(OH)D concentrations (54.3 ± 34.5 nmol/L) lower than Caucasian women (P = 0.04), but 
higher than African American women (P = 0.001). Vitamin D deficiency (25(OH)D < 50 nmol/L) 
was found in 86% of African American women, 35% of Caucasian women, and 56% of Hispanic 
women, whereas vitamin D insufficiency (25(OH)D 50-75 nmol/L) was found in 10% of African 
American women, 40% of Caucasian women, and 16% of Hispanic women in this cohort. 
African American women also had lower TAG concentrations than Caucasian (P = 0.002) and 
Hispanic women (P = 0.003). Similar to plasmas 25(OH)D concentrations, Caucasian women 
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had higher 25(OH)D/TAG ratios than African American women (1.85 ± 1.34 vs. 1.14 ± 0.94; P 
< 0.001) and Hispanic women 1.85 ± 1.34 vs. 1.40 ± 1.26; P = 0.03) (Table 1). 
Table 1. Maternal Characteristics by Race 
 
 
Maternal Characteristics 
 
 
African 
American 
n = 115 
 
 
Caucasian 
n = 159 
 
 
Hispanic 
and Other 
n = 25 
 
 
P-
value
a
 
 
 
P-
value
b
 
 
 
P-
value
c
 
 
 
Maternal age (yr) 
 
23.6 ± 4.5 
 
26.9 ± 4.4 
 
24.6 ± 5.2 
 
<0.001 
 
0.34 
 
0.02 
Maternal BMI (kg/m
2
) 28.4 ± 5.4 26.0 ± 4.8 28.5 ± 6.0
d 
<0.001 0.92 0.02 
Maternal years of education 12.3 ± 1.7 15.1 ± 3.0 13.0 ± 2.4 <0.001 0.27 0.001 
Gravidity, n (%) 
     1 
   ≥2 
 
35 (30.4) 
80 (69.6) 
 
69 (43.4) 
90 (56.6) 
 
5 (20.0) 
20 (80.0) 
0.04 0.42 0.05 
Smoking in pregnancy, n (%) 45 (39.1) 46 (28.9) 8 (32.0) 0.10 0.66 0.94 
Blood pressure at enrollment 
     Systolic (mmHg) 
     Diastolic (mmHg) 
 
114 ± 10.2 
68 ± 7.8 
 
115 ± 9.4 
69 ± 8.0 
 
108 ± 10.6 
66 ± 7.8 
 
0.13 
0.42 
 
0.02 
0.11 
 
0.001 
0.04 
Gestational age when prenatal 
vitamin use started (wk)
e
 
9.1 ± 4.0 4.3 ± 4.4 7.5 ± 4.7 <0.001 0.08 0.001 
Plasma 25(OH)D (nmol/L) 33.9 ± 20.8 64.2 ± 32.2 54.3 ± 34.5 <0.001 0.001 0.04 
Vitamin D status, n (%) 
     Deficient 
     Insufficient 
     Sufficient 
 
99 (86.1) 
12 (10.4) 
4 (3.5) 
 
55 (34.6) 
63 (39.6) 
41 (25.8) 
 
14 (56.0) 
4 (16.0) 
7 (28.0) 
<0.001 <0.001 0.05 
Plasma TAG (mg/dL) 36.4 ± 17.4 45.3 ± 30.7 53.3 ± 37.2 0.002 0.003 0.24 
25(OH)D/TAG ratio
f
 1.14 ± 0.94 1.85 ± 1.34 1.40 ± 1.26 <0.001 0.33 0.03 
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Table 1. Maternal Characteristics by Race (Continued) 
 
 
Maternal Characteristics 
 
 
African 
American 
n = 115 
 
 
Caucasian 
n = 159 
 
 
Hispanic 
and Other 
n = 25 
 
 
P-
value
a
 
 
 
P-
value
b
 
 
 
P-
value
c
 
 
 
Season of blood draw, n (%) 
     Spring (Mar-May) 
     Summer (Jun-Aug) 
     Autumn (Sep-Nov)  
     Winter (Dec-Feb) 
 
 
25 (21.7) 
38 (33.0) 
26 (22.6) 
26 (22.6) 
 
 
45 (28.3) 
47 (29.6) 
35 (22.0) 
32 (20.1) 
 
 
9 (36.0) 
6 (24.0) 
8 (32.0) 
2 (8.0) 
 
 
0.66 
 
 
0.16 
 
 
0.35 
a
p value between African American and Caucasian. 
b
p value between African American and Hispanic and Other. 
c
p value between Caucasian and Hispanic and Other. 
d
1 subject was excluded from the BMI analysis because measured weight was missing. 
e
7 subjects (5 African Americans and 2 Caucasians) were excluded from these analyses due to lack of information 
on prenatal vitamin use. 
f
25(OH)D/TAG ratio was calculated by dividing plasma 25(OH)D concentration (nmol/L) by plasma TAG 
concentration (mg/dL) 
 
Adverse Pregnancy Outcomes 
There were five cases of preeclampsia and 15 cases of GDM in this cohort. Although both 
preeclampsia and GDM were approximately two times more prevalent in the African American 
women compared with Caucasian women (data not shown), these differences did not reach 
statistical significance (P = 0.65 and P = 0.50 respectively). Eighty-nine (30%) women in this 
cohort had a cesarean delivery. No statistical significant differences in the rate of cesarean 
delivery were found between the race groups. 
Women with adverse pregnancy outcomes tended to have higher BMI, have higher blood 
pressure at enrollment, deliver their infants earlier, and have a larger chance of delivering a 
preterm infant, when compared with women with no adverse pregnancy outcomes in the index 
pregnancy (Table 2). No significant differences in gravidity, prenatal vitamin use, and smoking 
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status between women with adverse pregnancy outcomes and women without were observed. 
However, women with adverse pregnancy outcomes tended to have higher circulating TAG 
concentrations (46.9 ± 35.7 mg/dL vs. 40.2 ± 22.3 mg/dL; P = 0.04). 
Table 2. Characteristics between Women with and without Adverse Pregnancy Outcomes 
  
Women without 
adverse pregnancy 
outcomes 
n = 189 
 
 
Women with 
adverse pregnancy 
outcomes 
n = 92 
 
 
P-
value 
 
 
Maternal age 
 
25.0 ± 4.6 
 
26.6 ± 5.1 
 
0.01 
Maternal BMI (kg/m
2
) 26.6 ± 5.4
a
 28.3 ± 4.8 0.01 
Gravidity, n (%) 
     1 
   ≥2 
 
68 (36.0) 
121 (64.0) 
 
39 (42.4) 
53 (57.6) 
0.36 
Blood pressure at enrollment (mm Hg) 
     Systolic 
     Diastolic 
 
113 ± 9.1 
68 ± 7.7 
 
117 ± 11.0 
70 ± 8.3 
 
0.002 
0.04 
Prenatal vitamin use, n (%)
b
 184 (98.4) 91 (98.9) 0.99 
Smoking during pregnancy, n (%) 60 (31.7) 35 (38.0) 0.36 
Plasma 25(OH)D concentrations (nmol/L) 50.4 ±31.7 55.2 ± 31.9 0.22 
Plasma TAG concentrations (mg/dL) 40.2 ± 22.3 46.9 ± 35.7 0.04 
25(OH)D/TAG ratio
c
 1.56 ± 1.22 1.56 ± 1.35 0.79 
Gestational age at delivery (wk) 39.5 ± 1.3 38.9 ± 2.2 0.008 
Preterm <37 wk, n (%) 6 (3.2) 12 (13.0) 0.004 
a
1 subject was excluded from the BMI analysis because measured weight was missing. 
b
7 subjects were excluded from this analysis due to lack of information on prenatal vitamin use. 
c
25(OH)D/TAG ratio was calculated by dividing plasma 25(OH)D concentration (nmol/L) by plasma TAG 
concentration (mg/dL) 
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Maternal 25(OH)D Concentrations and Adverse Pregnancy Outcomes 
No statistically significant differences in maternal plasma 25(OH)D concentrations were 
found between non-preeclamptic women and preeclamptic women, between women without 
GDM and women with GDM, and between women delivered vaginally and women delivered by 
cesarean section (Table 3). Lower maternal 25(OH)D concentrations were associated with higher 
odds for preeclampsia (OR, 4.05; 95% CI, 0.45-36.71) and GDM (OR, 2.12; 95% CI, 0.71-6.38), 
but were not statistically significant (Table 4). Lower maternal 25(OH)D concentrations were 
also associated with lower odds for cesarean delivery (OR, 0.54; 95% CI, 0.32-0.89; P < 0.05). 
Exclusion of repeat cesarean deliveries from the analysis did not significantly affect the result 
(data not shown). Overall, lower maternal 25(OH)D concentrations were associated with lower 
odds for adverse pregnancy outcomes (OR, 0.65; 95% CI, 0.40-1.08), but results were not 
statistically significant. 
Maternal 25(OH)D/TAG Ratios and Adverse Pregnancy Outcomes 
Significantly lower 25(OH)D/TAG ratios were found in women with preeclampsia (0.67 ± 
0.56 vs. 1.55 ± 1.24; P = 0.04), and women with GDM (0.98 ± 0.83 vs. 1.59 ± 1.27; P = 0.02) 
(Table 3). Lower maternal 25(OH)D/TAG ratios were associated with higher odds for 
preeclampsia (OR, 4.05; 95% CI, 0.45-36.71), but not statistically significant (Table 4). However, 
the association between lower 25(OH)D/TAG ratios and increased odds for GDM (OR, 2.96, 
95% CI, 0.92-9.55) was almost significant (P = 0.07). 
There were no statistically significant differences in 25(OH)D/TAG ratios between women 
delivered vaginally and women delivered by cesarean section. Lower maternal 25(OH)D/TAG 
ratios were associated with lower odds for cesarean delivery (OR, 0.74; 95% CI, 0.45-1.22) and 
adverse pregnancy outcomes (OR, 0.80, 95% CI, 0.48-1.31), but results were not statistically 
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significant. Exclusion of repeat cesarean deliveries from the analysis did not significantly affect 
the result (data not shown). 
Table 3. Plasma 25(OH)D Concentrations and 25(OH)D/TAG Ratios Between Cases and 
Controls 
  
Non-
Preeclamptic 
n = 294 
 
 
 
Preeclamptic 
n = 5 
 
 
Non-GDM 
n = 266 
 
 
GDM 
n = 15 
 
 
Vaginal 
n = 210 
 
 
Cesarean 
n = 89 
 
25(OH)D 
(nmol/L) 
 
52.1 ± 32.0 
 
30.4 ± 14.1 
 
52.6 ± 32.1 
 
41.1 ± 24.6 
 
49.9 ± 31.8 
 
56.0 ± 31.8 
25(OH)D/ 
TAG
a
 
1.55 ± 1.24 0.67 ± 0.56* 1.59 ± 1.27 0.98 ± 0.83* 1.52 ± 1.19 1.58 ± 1.35 
a
25(OH)D/TAG ratio was calculated by dividing plasma 25(OH)D concentration (nmol/L) by plasma TAG 
concentration (mg/dL) 
*P-value <0.05 
 
Table 4. Odds Ratios and 95% Confidence Intervals for Pregnancy Outcomes According to 
2 Measures of Vitamin D Status 
  
25(OH)D 
< median 
 
 
>median 
 
25(OH)D/TAG
a
 
<median 
 
 
>median 
 
Preeclampsia 
 
4.05 [0.45-36.71] 
 
Ref 
 
4.05 [0.45-36.71] 
 
Ref 
GDM
b
 2.12 [0.71-6.38] Ref 2.96 [0.92-9.55] Ref 
Cesarean delivery 0.54 [0.32-0.89]* Ref 0.74 [0.45-1.22] Ref 
Adverse pregnancy outcomes
b
 0.65 [0.40-1.08] Ref 0.80 [0.48-1.31] Ref 
a
25(OH)D/TAG was calculated by dividing plasma 25(OH)D concentration (nmol/L) by plasma TAG concentration 
(mg/dL) 
b
18 subjects were excluded from these analyses due to lack of complete OGTT results. 
*P-value <0.05 
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Effects of Potential Confounders on Vitamin D Status 
Non-obese women (BMI < 30) tended to have higher plasma 25(OH)D concentrations (P < 
0.001), lower plasma TAG concentrations (P = 0.01), and higher 25(OH)D/TAG ratios (P < 
0.001) than obese women (BMI ≥ 30). Nulliparous women had higher 25(OH)D concentrations 
(P = 0.006) and 25(OH)D/TAG ratios (P = 0.02). There were no significant differences in 
25(OH)D and TAG concentrations or 25(OH)D/TAG ratios between women in different age 
groups, smokers and non-smokers, prenatal vitamin users and non-users at enrollment, and 
plasma samples collected in different seasons (Table 5). 
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Table 5. Plasma 25(OH)D Concentrations, TAG Concentrations and 25(OH)D/TAG Ratios 
between Maternal Groups 
  
Plasma 
25(OH)D 
concentrations 
(nmol/L) 
 
 
 
P-
value 
 
 
Plasma TAG 
concentrations 
(mg/dL) 
 
 
 
P-
value 
 
 
 
25(OH)D/TAG  
ratios
a
 
 
 
 
P-
value 
 
 
Maternal age 
     <30 yrs 
     ≥30 yrs 
 
 
50.9 ± 32.1 
55.3 ± 31.1 
 
 
0.26 
 
 
42.1 ± 28.8 
44.7 ± 20.9 
 
 
0.17 
 
 
1.54 ± 1.26 
1.52 ± 1.13 
 
 
0.93 
Maternal BMI
b
 
     <30 
     ≥30  
 
57.0 ± 32.7 
38.6 ± 25.7 
 
<0.001 
 
39.9 ± 21.0 
49.2 ± 39.0 
 
0.01 
 
1.74 ± 1.28 
1.05 ± 0.96 
 
<0.001 
Gravidity  
     1 
     ≥2 
 
57.3 ± 35.1 
48.5 ± 29.5 
 
0.006 
 
41.4 ± 22.1 
43.3 ± 30.2 
 
0.70 
 
1.74 ± 1.41 
1.42 ± 1.12 
 
0.02 
Smoking during 
pregnancy 
     Yes 
     No 
 
 
46.8 ± 26.8 
54.1 ± 33.9 
 
 
0.20 
 
 
44.6 ± 24.9 
41.5 ± 28.7 
 
 
0.31 
 
 
1.32 ± 0.96 
1.65 ± 1.34 
 
 
0.10 
Prenatal vitamin 
use
c
 
     Yes 
     No 
 
 
52.2 ± 32.0 
30.1 ± 18.6 
 
 
0.15 
 
 
42.6 ± 27.7 
45.9 ± 18.2 
 
 
0.56 
 
 
1.56 ± 1.24 
0.68 ± 0.28 
 
 
0.12 
Season of blood 
collection 
     Spring 
     Summer 
     Autumn  
     Winter 
 
 
56.1 ± 33.2 
52.2 ± 33.2 
50.2 ± 25.5 
46.9 ± 34.6 
 
 
>0.05 
 
 
45.1 ± 24.8 
43.1 ± 34.9 
42.2 ± 25.8 
38.8 ± 18.8 
 
 
>0.05 
 
 
1.47 ± 1.08 
1.55 ± 1.09 
1.64 ± 1.58 
1.49 ± 1.22 
 
 
 
>0.05 
a
25(OH)D/TAG ratios were calculated by dividing plasma 25(OH)D concentrations (nmol/L) by plasma TAG 
concentrations (mg/dL) 
b
1 subject was excluded from the BMI analysis because measured weight was missing. 
c
7 subjects were excluded from this analysis due to lack of information on prenatal vitamin use. 
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Chapter 5 
DISCUSSION 
Maternal 25(OH)D Concentrations and Adverse Pregnancy Outcomes 
Our findings suggested an association between lower maternal plasma 25(OH)D 
concentrations during early pregnancy with an increased subsequent risk for preeclampsia (OR, 
4.05; 95% CI, 0.45-36.71). This inverse association supports the findings of other studies on 
maternal vitamin D status and preeclampsia risk (8-11). However, the association reported in this 
study did not reach statistically significant level. The paucity of cases likely plays a role in this 
lack of statistical significance. This study only had 5 cases of preeclampsia. In contrast, the 
nested case-control study by Bodnar et al. (9) contained 55 cases and 219 controls, and found 
every 50-nmol/L decrease in serum 25(OH)D concentration <22 weeks of gestation doubled the 
risk of preeclampsia (adjusted OR, 2.4; 95% CI, 1.1-5.4). 
Our findings also reported an association between lower maternal plasma 25(OH)D 
concentrations during early pregnancy with an increased subsequent risk for GDM (OR, 2.12; 
95% CI, 0.71-6.38). Similar associations were found in several studies on maternal vitamin D 
status and GDM risk (12-14). Likewise, the association reported in this study was not statistically 
significant, probably due to the small number of GDM cases (n = 15). A nested case-control 
study including 57 GDM cases and 114 controls found that the risk for GDM in women with 
25(OH)D concentrations <50 nmol/L in early pregnancy was 2.66 times higher than those with 
25(OH)D concentrations >75 nmol/L (adjusted OR, 2.66; 95% CI, 1.01-7.02) (12). 
The results of this study suggested lower maternal 25(OH)D concentrations were 
significantly associated with a lower risk of cesarean delivery (OR, 0.54; 95% CI, 0.32-0.89).  
This finding is in contrast with the findings of another study, which reported a four-fold 
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increased risk for primary cesarean delivery associated with women with 25(OH)D 
concentrations <37.5 nmol/L (OR, 3.84; 95% CI, 1.71-8.62) (15). Our findings may not be 
comparable with that study because they measured their subjects’ serum 25(OH)D 
concentrations after delivery. Their results may reflect the effects of cesarean delivery on 
maternal vitamin D status instead. Bowyer et al. (25) also included both primary and repeat 
cesarean deliveries in their study, and they found no significant association between maternal 
vitamin D status in the third trimester and risk for cesarean delivery. 
Maternal 25(OH)D/TAG Ratios and Adverse Pregnancy Outcomes 
We hypothesized the 25(OH)D/TAG ratio may be a better indicator of vitamin D status, and 
thus a better predictor of adverse pregnancy outcomes. Women with preeclampsia and GDM had 
significantly lower 25(OH)D/TAG ratios than women without preeclampsia and GDM 
respectively, but their plasma 25(OH)D concentrations were not significantly different. Similar 
to plasma 25(OH)D concentrations, our findings suggested an association between lower 
maternal 25(OH)D/TAG ratios and an increased subsequent risk for preeclampsia (OR, 4.05; 
95% CI, 0.45-36.71), but this association did not reach statistical significance. Our findings also 
suggested a 3-fold increased risk for GDM associated with lower maternal 25(OH)D/TAG ratios 
(OR, 2.96; 95% CI 0.92-9.55). This association was near to statistically significant (P = 0.07), 
and was much more significant than the association between maternal 25(OH)D concentrations 
and GDM risk (P = 0.19). Likewise, the small number of diagnoses of preeclampsia and GDM in 
this cohort could contribute to the lack of statistical significance in the findings on preeclampsia 
and GDM. Our findings also suggested a positive association between maternal 25(OH)D/TAG 
ratios and risk for cesarean delivery (OR, 0.74; 95% CI, 0.45-1.22), but this association was not 
statistically significant. 
25 
 
Although neither 25(OH)D concentrations nor 25(OH)D/TAG ratios were proved to be 
significantly associated with the risk of preeclampsia and GDM in our study, our hypothesis that 
25(OH)D/TAG is a better indicator of maternal vitamin D status is still possible. In our study, 
25(OH)D/TAG ratios were associated with the risk of the adverse pregnancy outcomes in a 
manner similar to 25(OH)D concentrations, and the associations were more significant compared 
to 25(OH)D concentration alone. 
Effects of Potential Confounders on Vitamin D Status 
In this study, obesity was found to be associated with lower plasma 25(OH)D concentrations 
(P < 0.001), and 25(OH)D/TAG ratios (P < 0.001). This is consistent with previous findings of 
lower bioavailability of vitamin D in obese people because of possible sequestration of vitamin 
D in subcutaneous fat (63). Also, nulliparity was associated with higher 25(OH)D concentrations 
(P = 0.006) and 25(OH)D/TAG ratios (P = 0.02). These maternal factors may have confounding 
effects on the results and contribute to the lack of statistical significance of our findings. 
Seasonal effects on circulating 25(OH)D concentrations were not found in this study. This 
suggests that vitamin D synthesis in the skin was not a significant contributor to vitamin D status 
of pregnant women in this cohort. 
Limitations 
The present study has several limitations. Firstly, only a few subjects were diagnosed with 
preeclampsia or GDM. Therefore, the findings regarding these pregnancy outcomes did not reach 
statistical significance, and thus conclusion of whether or not maternal vitamin D status has an 
effect on these two outcomes could not be made in this study. Secondly, the reasons for cesarean 
delivery were not collected, so the adverse effect of higher maternal vitamin D status on the risk 
of cesarean delivery suggested by our findings could not be explained in this study. 
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The fact that the study subjects might have been taking DHA capsules during their pregnancy 
may be a limitation as well, because higher n-3 fatty acid intake may also reduce the risk of 
preeclampsia (10). Our findings may have been confounded by the effect of DHA on pregnancy 
outcomes. Assessment of the confounding effect of DHA is not possible before October 2011 
because we are still blinded to the capsule assignment until then. Another limitation is the plasma 
samples have been stored for up to five years and have been thawed and refrozen. However, 
serum 25(OH)D and TAG has been reported to be stable in storage and was unaffected after up 
to four freeze-thaw cycles (64-67). To assess the effect of storage on 25(OH)D and TAG 
concentrations in the samples, we divided the plasma samples into two groups—samples 
collected in 2006-2007 and samples collected in 2008-2009. The mean 25(OH)D concentration 
of older samples was about 7 nmol/L lower than the mean of newer samples, though not 
statistically significant (P = 0.07), but there were no significant differences in TAG 
concentrations and 25(OH)D/TAG ratios between older and new samples. Therefore, sample 
storage may not significantly affect our findings. Also, this study used a sample of convenience, 
and the results may not sufficiently represent all pregnant women in the US. Finally, the ELISA 
kit has a 100% cross-reactivity of 25(OH)D3 and 24,25(OH)2D3, and a 67.8% cross-reactivity of 
25(OH)D2  (61). The accuracy of measurements could thus be compromised because the assay 
measured 24,25(OH)2D3 as well, and plasma 25(OH)D concentrations would be underestimated 
when a subject’s major source of vitamin D was in the form of vitamin D2. 
Implications 
We measured maternal vitamin D status before the diagnosis of preeclampsia and GDM. 
Therefore, the increased risk associated with lower plasma 25(OH)D concentrations and 
25(OH)D/TAG ratios suggested by our findings, though not statistically significant, is more 
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likely to be a consequence, rather than a cause, of suboptimal maternal vitamin D status. This 
suggests that maternal vitamin D status during early pregnancy may be an important predictor of 
pregnancy outcomes. 
Although more than 98% of our subjects reported prenatal vitamin consumption at 
enrollment, 56% and 26% of the pregnant women in our study were vitamin D deficient 
(25(OH)D < 50 nmol/L) and insufficient (25(OH)D 50-75 nmol/L), respectively. This large 
number of pregnant women with suboptimal vitamin D status in our study suggests that the 
amount of vitamin D in prenatal vitamin supplements may be inadequate. 
The mean plasma 25(OH)D concentration of African American women was almost half of 
that of Caucasian women in this study (33.9 ± 20.8 nmol/L vs. 64.2 ± 32.2 nmol/L; P < 0.001). 
This racial disparity in vitamin D status during pregnancy may partly explain the higher 
morbidity and mortality rates among African Americans due to the potential adverse effects 
caused by poor vitamin D status during pregnancy and infancy. Maintaining a sufficient vitamin 
D status is possibly a means to reduce the health disparities in the US. 
Future Studies 
The statistical significance of our findings was limited by the small number of preeclampsia 
and GDM cases in the cohort. Similar studies with higher number of cases are needed to yield 
statistically significant findings to confirm the effects of maternal vitamin D status on pregnancy 
outcomes, and whether 25(OH)D/TAG ratio predicts pregnancy outcomes better than plasma 
25(OH)D concentration alone. Maternal vitamin D status during pregnancy was inversely 
associated with the subsequent risk of cesarean delivery in this study. Further analyses exploring 
the association between maternal vitamin D status and specific indications for cesarean delivery 
are needed to clarify the role of vitamin D in delivery. Future randomized control trials to verify 
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the benefits of vitamin D supplementation on pregnancy outcomes are also required to justify the 
need to revise the recommendations regarding vitamin D intake and supplementation during 
pregnancy and the need for future vitamin D-related policies or programs to improve the vitamin 
D status of pregnant women in the US. 
Conclusion 
Our findings found no significant relationship between maternal vitamin D status and the 
risks of preeclampsia and GDM due to the small number of these events in the cohort. When 
using 25(OH)D/TAG ratio, in place of 25(OH)D concentrations, as the indicator of vitamin D 
status, an almost statistically significant association between lower maternal vitamin D status and 
increased GDM risk was observed. 
Our study also showed a reduced risk of cesarean delivery in women with lower 25(OH)D 
concentrations. When using 25(OH)D/TAG ratio was used in the analysis instead, this 
association was attenuated and no  longer significant. Additional delivery information is needed 
to explain this association between maternal vitamin D status and the risk of cesarean delivery. 
Maternal 25(OH)D/TAG ratio may be a better indicator of vitamin D status during pregnancy. 
Due to the lack of statistically significant findings in our study, further investigations into this 
hypothesis should be done in studies with a larger number of adverse pregnancy events. 
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Chapter 6 
SUMMARY 
This study aimed to assess the effects of maternal vitamin D status on the subsequent risk for 
pregnancy complications and to determine if plasma 25(OH)D concentrations should be adjusted 
for plasma TAG concentrations when assessing vitamin D status in pregnant women. 
We obtained the data of 299 pregnant women in the KUDOS trial who had their delivery 
information available. We measured 25(OH)D and TAG concentrations in the plasma samples 
collected from these women in their 8
th
 to 20
th
 week of gestation using 25(OH)D ELISA kit and 
triglyceride assay kit respectively. We then assessed the relationship of plasma 25(OH)D 
concentrations and 25(OH)D/TAG ratios to the risk of preeclampsia, GDM, and cesarean 
delivery. 
Preeclampsia was diagnosed in five women, GDM was diagnosed in 15 women and 89 
cesarean deliveries were observed. 96% of African American women, 74% of Caucasian women, 
and 72% of Hispanic women in this cohort had plasma 25(OH)D concentrations less than 75 
nmol/L. Mean 25(OH)D concentrations of African American, Caucasian, and Hispanic women 
were 33.9 ± 20.8, 64.2 ± 32.2, and 54.3 ± 34.5 nmol/L respectively. Mean 25(OH)/D ratios of 
African American, Caucasian, and Hispanic women were 1.14 ± 0.94, 1.85 ± 1.34, and 1.40 ± 
1.26 respectively. Vitamin D status of African American women and Hispanic women were 
significantly lower than Caucasian women (P < 0.05). However, African American women and 
Hispanic women were also higher in BMI and were more likely to be multiparous compared to 
Caucasian women in this study (P ≤ 0.05). Both increased BMI and increased parity were 
associated with lower vitamin D status in these race groups (P < 0.05). 
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Women who subsequently developed preeclampsia (0.67 ± 0.56 vs. 1.55 ± 1.24; P = 0.04) or 
GDM (0.98 ± 0.83 vs. 1.59 ± 1.27; P = 0.02) had significantly lower 25(OH)D/TAG ratios, 
compared to women who did not. The 25(OH)D/TAG ratios were not significantly different 
between women with different delivery modes. 
Women with 25(OH)D concentrations below median had increased odds of preeclampsia 
(OR, 4.05; 95% CI, 0.45-36.71) and GDM (OR, 2.12; 95% CI, 0.71-6.38). Both associations did 
not reach statistical significance as a result of the small number of preeclampsia and GDM cases. 
A reduced risk of cesarean delivery was significantly associated with lower 25(OH)D 
concentrations (OR, 0.54; 95% CI, 0.32-0.89). This finding was not explained by the inclusion of 
repeat cesarean delivery in the analysis. 
Women with 25(OH)D/TAG ratios below median had increased odds of preeclampsia (OR, 
4.05; 95% CI, 0.45-36.71), but this relationship was not statistically significant similarly due to 
the small number of preeclampsia cases in the study. A close to statistically significant 
association (P = 0.07) between lower 25(OH)D/TAG ratio and increased GDM risk was 
observed (OR, 2.96, 95% CI, 0.92-9.55). Likewise, an association between lower 25(OH)D/TAG 
ratio and reduced odds for cesarean delivery, but not statistically significant, was found in our 
study (OR, 0.74; 95% CI, 0.45-1.22).  
Our findings supported our hypothesis that lower maternal vitamin D status is associated 
with increased risks of preeclampsia and GDM. The small number of preeclampsia and GDM 
cases in our study may explain the lack of statistical significance of our findings on these adverse 
outcomes. The positive correlation between maternal vitamin D status and risk of cesarean 
delivery reported is in conflict with our hypothesis and the finding of a previous study on 
maternal vitamin D status and risk of primary cesarean delivery. A better evaluation of the 
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relationship between maternal vitamin D status and the subsequent risk of cesarean delivery may 
be possible after including the indications for cesarean delivery in the statistical analysis. 
Maternal 25(OH)D/TAG may be a better indicator of maternal vitamin D  because 
25(OH)D/TAG ratios were associated with the risk of the adverse pregnancy outcomes in a 
manner similar to 25(OH)D concentrations, and the associations were more significant compared 
to 25(OH)D concentration alone. Future studies with larger number of preeclampsia and GDM 
diagnoses are needed to confirm the effects of maternal vitamin D status on these pregnancy 
outcomes and to determine if plasma 25(OH)D concentrations should be adjusted for TAG 
concentrations to better indicate maternal vitamin D status. 
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APPENDIX A 
25(OH)D Assay  
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Plasma 25(OH)D concentration is measured using an ELISA kit (Immundiagnostik AG, 
Bensheim, Germany). More detailed procedures are available in the kit manual (61). 
Principle of the Assay 
Plasma samples are incubated with the releasing agent to release DBP-bound 25(OH)D from 
the DBP. After the addition of the samples and the anti 25(OH)D antibody to the microtiter plate 
precoated with 25(OH)D, there is a competition between the 25(OH)D in the samples and a fixed 
quantity of 25(OH)D bound to the wells of the plate for the binding of the antibody. Addition of 
peroxidase-conjugated antibody to the wells leads to the formation of 25(OH)D-anti 25(OH)D 
antibody-peroxidase conjugate complexes. Tetramethylbenzidine (TMB) acts as a peroxidase 
substrate when it is added to the complexes. An acidic solution is then added to stop the reaction. 
The contents of the wells change from blue to yellow in color. The intensity of the yellow color 
is inversely proportional to the 25(OH)D concentration of the starting samples. 25(OH)D 
concentrations of the plasma samples are determined by comparing the absorbance values to the 
dose response curve obtained from the standards. 
Procedure 
1. Label a 1.5 mL Eppendorf tube for each standard, control, and plasma sample. 
2. Pipette 30 μL of standards or plasma samples or controls into their corresponding tubes. 
3. Add 300 μL of releasing reagent into each tube and vortex briefly. 
4. Incubate the tubes for 1 hour at 37 °C in a water bath or heating block. 
5. Add 600 μL of sample dilution buffer into each tube and vortex carefully. 
6. Pipette 100 μL of the mixture of each tube into 2 designated wells, 50 μL each, of the 96-
well microtiter plate. 
7. Add 150 μL of anti 25(OH)D antibody solution into each well. 
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8. Cover the plate tightly and incubate for 18-22 hours at 8-10 °C in the dark. 
9. Aspirate and wash the wells 5 times with 250 μL of diluted wash buffer using an 8-channel 
pipette. After the last wash, hit the plate against paper towel to remove the residual wash 
buffer in the wells. 
10. Add 200 μL of peroxidase-conjugated antibody solution into each well 
11. Cover the plate tightly and incubate for 1 hour at room temperature while shaking with a 
horizontal microtiter plate shaker. 
12. Aspirate and well the wells 5 times with 250 μL of diluted wash buffer using an 8-channel 
pipette. After the last wash, hit the plate against paper towel to remove the residual wash 
buffer in the wells. 
13. Add 200 μL of TMB substrate into each well 
14. Incubate for 10-15 minutes at room temperature in the dark. 
15. Add 50 μL of ELISA stop solution into each well. 
16. Read the plate with a microtiter plate reader at 450 nm. 
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APPENDIX B 
Triacylglycerol Assay 
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Plasma TAG analysis was done by a triglyceride assay kit from Cayman Chemical Company, 
Michigan, USA. More detailed procedures are found in the kit manual (62). 
Principle of the Assay 
During the assay, triglycerides are hydrolyzed into glycerol and fatty acids through the action 
of lipoprotein lipase. The glycerol is phosphorylated by glycerol kinase to form glycerol-3-
phosphate, which then reacts with oxygen to produce dihydroxyacetone phosphate and hydrogen 
peroxide in a reaction catalyzed by glycerol phosphate oxidase. The hydrogen peroxide reacts 
with 4-aminoantipyrine and N-Ethyl-N-(3-sulfopropyl)-m-anisidine, and the quinoeimine dye 
forms (with a purple color of various intensities, depending on the TAG concentration to start 
with). This reaction is catalyzed by peroxidase. TAG concentrations were determined by 
comparing the absorbance values of the samples with the standard curve obtained from the 
triglyceride standards. 
Procedure 
1. Label 8 1.5 mL Eppendorf tubes 1 to 8. Add 200 μL of triglyceride standard diluent to tubes 
2-8 and 400 μL to tube 1. Add 100 μL of triglyceride standard to tube 1 and vortex. Transfer 
200 μL from tube 1 to tube 2 and vortex tube 2. Transfer 200 μL from tube 2 to tube 3 and 
vortex tube 3. Repeat this process for tubes 4-7. After this serial dilution, the triglyceride 
concentrations of tubes 1-8 are 200, 100, 50, 25, 12.5, 6.25, 3.125 and 0 mg/dL respectively. 
2. Add 10 μL of the 8 tubes to their designated wells on the 96-well plate in duplicate. 
3. Add 10 μL of each plasma sample to their designated wells in duplicate. 
4. Add 150 μL of diluted enzyme buffer solution to each well. 
5. Mix the solution in the wells by carefully shaking the plate for several seconds with a 
horizontal microtiter plate shaker. 
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6. Incubated for 15 minutes at room temperature. 
7. Read the absorbance of the wells at 540 nm using a plate reader.  
 
 
 
 
 
 
 
 
 
 
 
 
 
